Realising the promise of genomic testing across oncology
Unlocking the secrets of the human genome has long been an ambitious pursuit for researchers around the world. Over the past two decades, innovative research […]
Deep Dive
Realising the promise of cancer vaccines
For years, the promise of therapeutic cancer vaccines has intrigued researchers working in the oncology space. And for good reason. The concept of pre-emptively training […]
Deep Dive: Oncology 2022
Eradicating cancer is an ambitious goal for oncologists and life science companies around the world. But, with a growing number of cancer treatments entering the […]
ICSs: improving patient and market access at a local level
Integrated Care Systems (ICSs) – 42 partnerships of health and care organisations who will plan and deliver more joined-up services for their locality in England […]
Time is motor neurons – the importance of newborn screening in SMA
Spinal muscular atrophy (SMA) is a devastating, genetic neuromuscular disease caused by a lack of a functional SMN1 gene that results in the progressive and […]
Is it time to rethink electronic prescribing in the US?
It is a fact of life that most – if not all – patients will require some form of prescription medication during their lifetime. Generally, […]
Combination pricing: access to the future of oncology treatment relies on collaboration
Combination therapies are fast becoming the cornerstone of cancer treatment: not just in the UK, but across the world. With strong evidence to support how […]
Closing the digital expectation gap in pharma
Jan Deman is Takeda’s head of digital customer experience for Europe and Canada. But he’d prefer not to refer to what he does as “innovation”. […]
How do we make patient centricity a reality?
For years, the subject of fostering direct connections with patients has been highlighted by notable figures across the healthcare and life sciences industries as a […]
Leveraging KOL insights to succeed in a data-driven world
For years, key opinion leaders (KOLs) have held a position of authority and respect amongst those working across the life science industry, be it a […]
Rethinking value: why diverse viewpoints matter
Value is a tricky concept to capture accurately. Given the diverse and complex world that we live in, different people will often hold contrasting views […]
Deep Dive: Market Access
For life science companies around the world, enabling faster access to innovative drugs and therapies is a complicated challenge. As this issue’s contributors discuss, changes […]
Emerging technologies that are changing the way healthcare is delivered in 2022
Wherever you consider the medical industry, you will find several new technologies being used to make new medicines, vaccines, and fight illnesses. The purpose is […]
Why VCs fell in love with pharma R&D in 2021
For many years, those inside the pharma industry have been telling the same old story about innovation: pharma is big, slow, and risk averse. Start-ups […]
Does the answer to advancing rare disease treatment lie in real-world data?
What do 300 million people have in common? They are living with rare diseases that are defined by their scarcity within the general population. In […]
Using cross-functional teams to develop a product’s value story
Tanya Brinsden, senior VP of operations at ICON Global Medical Communications and Pubs Hub, Jessica Cherian, VP of content and strategic services at ICON Market […]
Think global, act local: rethinking commercialisation models
The global market for life sciences is changing rapidly. Fuelled by technological advancements and a global pandemic, there are more opportunities than ever for companies […]
Amplifying the voices in rare diseases
There are approximately 300 million people around the world living with a rare disease. Yet, until relatively recently, there was limited focus on this heterogenous […]
Deep Dive: Research and Development
Fuelled by advancements in technology and computing, R&D in life sciences is undergoing a fundamental transformation that puts patients at the heart of research. Read […]
Accelerating patient engagement in the digital health era
Understanding the person behind the patient is a crucial part of medicine, one that healthcare providers can use to improve the efficacy of treatments. At […]
Pushing the right buttons for transformative digital health
Digital health and technologies offer a wealth of opportunities, but digital needs to become part of a company’s DNA to achieve transformation. Rodamni Peppa, Boston […]
Powered by digital: driving transformation and innovation in healthcare
Digital health is transforming the way that we approach healthcare, but how can companies make the most of this new multi-channel engagement model? Dr Paul […]
Digital health: making medicine more human
Covid-19 has lit a fire under the medical industry, driving them to re-evaluate and incorporate digital engagement models. Now, healthcare companies have a unique opportunity […]
Optimised clinical research through decentralised trials
Not only did the COVID-19 pandemic bring lockdown rules and increased safety protocols, it also led to delays, reconfigurations, limited patient access, and other restrictions […]
A multi-platform approach: the future of patient services
Andy Graves and Dr Clare Moloney of IQVIA discuss how the COVID-19 pandemic accelerated the adoption of digital patient services and how future deployment alongside […]
Understanding the prevention and treatment needs for cardiovascular disease
What does the current picture of cardiovascular disease in Europe look like? Surprisingly for many, cardiovascular disease (CVD) is Europe’s leading cause of death – […]
The rise, acceleration and acceptance of telehealth adoption
‘Healing at a distance’ is the literal meaning of telemedicine. According to the World Health Organization, it is defined as the use of ICT to […]
Targeted agents and immunotherapies
Targeted agents and immunotherapies are two of the most promising areas for significant advancements in cancer treatment. Envision Pharma’s scientific solutions division lead Rebecca Goldstein, […]
Deep Dive: Digital Health 2021
There is no doubt that the COVID-19 pandemic has accelerated the adopt of digital health. As this issue’s contributors discuss, the rapid transition to digital […]
How the combination treatment challenge impacts patients and how we are working together to solve it
How the combination treatment challenge impacts patients Access to medicines attracts a great deal of interest from patients, clinicians, and the public and there have […]
Recruiting patients to increase diversity & inclusion in clinical trials: one size does not fit all
More so now than ever, the inclusion of more diverse, and often more relevant, study populations is gathering momentum within the clinical trial community. From […]
The booming life sciences sector needs dynamic real estate support
Bruntwood SciTech is the UK’s leading property provider dedicated to driving the growth of the science and technology sector. UK life sciences are buoyant with […]
How biomarkers and bioanalytics are changing R&D
Biomarkers have been causing a paradigm shift in how HCPs treat patients for some time – now they are bringing the pharma industry a new […]
Health literacy for the intellectually disabled: is pharma doing enough?
What is health literacy and why is it important? Health literacy (HL), defined by the CDC as the degree to which individuals have the ability […]
Leveraging real-world data to meet payers’ needs
Payers are becoming savvier in accepting real-world data. Certara’s Lee Stern and Shawn Bates discuss the challenges and how pharma can use real-world data to […]
Time for a new model in patient access
Mig Sleeper, vice president, Global Pricing for Astellas Pharma Europe, explains why we must rethink how value is defined as we enter a new technological […]
Time to take patient engagement to the next level
Patient engagement in pharma is evolving, with some companies doing it better than others. Envision Pharma Group’s Dawn Lobban and Sarah Avent discuss the need […]
Patients want to be heard. Is pharma listening?
A common theme heard from the advocacy groups AXON works with is “Nothing for us without us,” says Natalie Turner, director at AXON, a global […]
Three views on technology improving clinical trial efficiency
Marie Emms, vice president of site and patient participation at Syneos Health, tells us technology helped increase patient enrolment, improve diversity and inclusion, and boost […]
Emerging from the shadow of COVID-19
We now have a unique opportunity to re-discover what matters most to patients, says Alnylam’s Kasha Witkos. In the biotech industry, if you are not […]
Deep Dive: Patients and Partnerships
As the world is slowly, gradually, hopefully emerges from the shadow of COVID-19 there’s a unique opportunity to re-discover what matters most to patients. In […]
How are the European pharma and biotech sectors addressing strategic communications?
Stakeholder expectations are high and, with all eyes on healthcare at the moment, it is essential for companies to go beyond generic commitments, says Rosanna […]
BMS’ Catherine Owen: Hybrid communication is here to stay
The company’s senior vice president for major markets (Europe, Canada and Japan) talks about the continued evolution of pharma’s approach to communications and commercialisation. The […]
A Life in a Day by The Method
Patient centricity has become a key aspiration for the pharma industry over the last several years, but getting entire organisations to think and behave in […]
Translating EU presence to US market success
Companies looking to replicate a drug’s EU market success in the US will face significant hurdles unless they are fully aware of the ever-changing national […]
Navigating the patient maze – pharma’s evolving challenge
Pharma companies are embracing patient centricity in drug development more than ever before. Over the last decade, leaders in the industry have championed patient engagement, […]
It’s time to rethink the physician-pharma relationship
The traditional sales channel for the pharmaceutical industry has centered on face-to-face interaction with its core target audience – prescribing physicians. What happens when suddenly […]
Refining digital collaboration
Pharmaceutical companies are traditionally more conservative with their approach to and incorporation of new technologies; however, prior to COVID, the industry had begun moving toward […]
Closing pharma’s communication gap with patients
The pharma industry has been talking about being patient-centric for years, but often that rhetoric hasn’t been accompanied by real change in the way product […]
Leveraging a strong product launch to build a successful pharma brand
So much effort goes into ensuring the successful launch of a new pharmaceutical product or indication, but it’s only once that has been achieved that […]
The post-pandemic evolution of pharma-doctor digital interactions
M3’s Tim Russell and Maxim Polyakov, together with Digital Futureway’s Heather Hancock, discuss new research on how doctor engagement has been altered by COVID-19. COVID-19 […]
Deep Dive: Communications and Commercialisation
The COVID-19 pandemic kickstarted a period of profound change in how the pharmaceutical industry approaches both communications and commercialisation. In some cases it was an […]
Cancer research faces uncertain post-COVID landscape
There’s a bright future ahead for cancer research in the UK, but only if the government is able to implement a clear plan for funding […]
Surprise pandemic lessons for pharma
Ask people in most western nations to think back to 2019 and consider what they would have said then about the potential impact of a […]
Lessons from the first generation of cell and gene oncology trials
Advances in cell and gene science are paving the way for transformative cancer treatments, but there are still many complexities in delivering clinical trials for […]
Oncology R&D: the patient insights we’re still missing, and how to catch up
Imagine you are a pharma executive working in oncology R&D. The landscape is rapidly becoming more competitive and overcrowded. You are under pressure to bring […]
Digital tools key to immuno-oncology’s future: report
If ASCO 2021 proves anything, it’s that the explosion in immuno-oncology therapies over the last few years shows no signs of slowing down. As the […]
Oncology and a year of COVID: lessons for the future
COVID’s impact on cancer care and oncology research has been devastating, but the pandemic has also opened up opportunities to take learnings and create long-lasting […]
How hybrid virtual engagement is accelerating oncology communication
COVID has revolutionised the way pharma engages with healthcare stakeholders – but to be truly successful, digital engagement needs to move away from an overreliance […]
Enabling healthcare’s digital future
Debiopharm Innovation Fund’s Tanja Dowe on investing in digital health start-ups and supporting them on their rollercoaster rides to improve patient outcomes The weight of […]
Digital health developments: a new investment era for start-ups
Healthware Labs’ Kristin Milburn explores how digital health start-ups can harness the huge potential for the sector in a post-COVID world and the paths they […]
Why pharma shouldn’t forget about sites in a post-COVID world
The pandemic forced massive changes to oncology sites to ensure patient safety and research continuity – but we must recalibrate and work with sites to […]
How digital pathways are changing healthcare
As demonstrated throughout COVID, digital health is no longer experimental. Digital technologies are proving their value by allowing for better care, improved adherence and a […]
Turning words into actions with patient engagement
Boehringer Ingelheim’s Carinne Brouillon tells us how the company co-created its recent Global Patient Partnership Summit with patients and how the meeting brought representatives together […]
Turning words into actions with patient engagement
Boehringer Ingelheim’s Carinne Brouillon tells us how the company co-created its recent Global Patient Partnership Summit with patients and how the meeting brought representatives together […]
How the patient voice is becoming vital for drug approval
Rebecca Sanders from Lipodystrophy UK tells us how the patient voice helped convince NICE to approve a much-needed drug for this rare disease, and explores […]
“A long way to go” for digital health reimbursement
A recent analysis delves into the challenges companies face in getting digital health technologies reimbursed and presents recommendations for how these products can find a […]
Time for a NICE change
The National Institute for Health and Care Excellence (NICE) is world-renowned for their work assessing the clinical and cost-effectiveness of new treatments. In recognition of […]
Rethinking access barriers to innovation
Market access issues don’t stop once a product has passed HTA – and this is especially true for disruptive therapies like ATMPs. Experts from Executive […]
AI meets RWE: The future of drug assessment?
Savana’s Dr Ignacio Medrano explains how machine learning and natural language processing technology is opening up huge amounts of previously-inaccessible real-world evidence (RWE) for pharma […]
Listening to ultra-rare disease communities
When it comes to ultra-rare diseases, the smaller the patient population, the bigger the challenges. As a global commercial biopharmaceutical company pioneering therapies for ultra-rare […]
How to improve payer engagement with tailored value communication
Pharmaceutical drug success rests on being able to achieve market access. Brands are facing increasing pressure to demonstrate strong value propositions in increasingly crowded therapeutic […]
From representation to empowerment: Putting patients at the centre of medicine reimbursement
Experts from Vynamic discuss their vision for a future where patients are at the heart of medicine reimbursement in Europe – and provide actionable steps […]
How will NICE fare in a post-Brexit world?
NICE has a global reputation as a pioneering HTA – but is that influence at risk now that the UK has left the EU? Experts […]
Research predicts the post-COVID landscape for HCP engagement
IQVIA’s Liz Murray takes us through the company’s latest research into HCPs’ attitudes to pharma engagement, and asks how pharma sales forces can adapt for […]
A year on: pandemic driven trends in HCP engagement
IQVIA’s John Procter explores why the industry should be paying attention to the changing HCP customer experience in the wake of COVID-19. This article appears […]
Deep Dive: Market Access
It’s fair to say this is the most interesting time ever for market access. Not only has COVID forced companies, governments and healthcare systems to […]
Culture changes – FUJIFILM Irvine Scientific’s COO on cell therapy, COVID vaccines and 50 years of the company
From animal processing, to cell therapy and AI, Tim Mullane, president, and chief operating officer tells pharmaphorum how FUJIFILM Irvine Scientific has evolved to become […]
LEO Pharma’s new R&D lead on driving agility in drug development
After 27 years at Bayer, Jörg Möller has moved to LEO Pharma as the company’s EVP, global research and development. We spoke to him about […]
Inside the UK’s leading efforts to restart clinical research
A herculean national effort has seen 69% of paused studies due to COVID restarted under the National Institute for Health Research’s (NIHR) Restart Framework. Experts […]
Focus on Rare: the invisible burden of rare diseases
Emma Sutcliffe from NexGen Healthcare Communications looks at how patient insights can bring the invisible challenges of living with a rare condition into plain view. […]
The post-COVID face of pharma research and development
The acute phase of the COVID-19 pandemic not only brought delays, restrictions, and reconfigurations to pharmaceutical research & development in 2020, but also a more […]
Deep Dive: Research and Development
Pharma’s historic R&D efforts have given us some light at the end of the COVID tunnel. Now it’s time for the industry to start doing […]
Patient partnerships: putting relevance into relationships
There are perhaps two ways to look at 2020 – on the surface, it has been a year of pandemic health catastrophe, on a deeper […]
3 practical steps for improving patient support
Research Partnership’s Emilie Braund and Harrison Gaiger dig down into the top insights pharma companies can harness to make their patient support programmes as powerful […]
A collaborative approach to greater diversity in clinical trials
The need for diversity in clinical trial populations has been a topic of discussion across regulators and the industry in general for decades. Despite the […]
Enabling new models of care: pursuing pharma’s partnership potential
There is a huge, ongoing shift in how health and wellness is approached in the UK, and the changes will have important implications for NHS-industry […]
‘No going back’ for clinical trials after COVID
Trial sites have adapted swiftly to the restrictions of COVID-19, and patients have seen many knock-on benefits as a result. The next step is ensuring […]
How patient insights are changing trial solutions
Patients have been asking for patient-centric trial solutions for years – the industry just hasn’t been listening. That’s according to Medidata’s Anthony Costello, who was […]
True patient-focused research through decentralised and hybrid trials
How can pharma improve the patient-centricity of its trials during COVID-19 and beyond? Experts from across the sector give their thoughts on the key approaches […]
Boosting the impact of patient services
New research from Accenture has revealed that adoption of patient support services hasn’t improved since 2015 despite increasing pharma investment. The company’s Jennifer Spada tells […]
Finding agility in unprecedented times
Nicole Farmer, general manager, UK & Ireland at Sanofi Genzyme, tells us how the company aimed for agile adaptation during COVID-19, and how these lessons […]
Patient journeys in the era of COVID-19
OPEN Health’s Richard Jones and Sumira Riaz assess the pandemic’s implications for understanding patients’ experiences and how the pharma industry can support them It’s impossible […]
How pharma needs to change for the era of digital health
Experts from Healthware Group explore how companies can rebuild their approach to digital from the ground up for the benefit of patients. Digital is not […]
Deep Dive: Patients and Partnerships
As this issue’s title suggests, patient centricity is about more than just talking points and marketing strategies – it requires companies to truly listen to, […]
VR, COVID and ensuring safety with cutting-edge tech
Not too long ago virtual reality (VR) tech might have seemed like a dream, but now it’s being harnessed by the healthcare industry for a […]
Navigating the NHS as a digital start-up
We speak to finalists from the Greater Manchester Future of Health accelerator to find out how digital start-ups can overcome the challenges small companies face […]
A pivotal moment for digital health adoption
Former chief digital officer for the NHS, Juliet Bauer, is now applying her experience to the private sector through video consultation firm Livi. She shares […]
What will the digital health ecosystem look like post-COVID?
COVID-19 has turned the world on its head and healthcare systems have had to respond rapidly to match the sudden changes created by lockdown. Digital […]
3 innovations booming during COVID and how to adopt them successfully
Research Partnership’s Vicki Newlove explores research into digital change during COVID-19 to find out what business questions pharma needs to address to succeed with innovations. […]
Digital therapeutics: Why human psychology is key to adoption
The healthcare system is running at its limits in many countries worldwide. One reason is the growing demand for healthcare, largely driven by the rise […]
Building the infrastructure for successful digital health start-ups
2020 might go down as the year digital health truly began to boom – but to continue thriving, health tech start-ups will need a strong […]
Two decades of digital: the changing habits of pharma and HCPs
When Chris Cooper of EPG Health launched his ‘European Prescriber Guide’ software twenty years ago, he was among a select few taking digital in pharma […]
Germany’s digital health changes will boost digital therapeutics in Europe
Digital therapeutics are gaining momentum worldwide and offer developers, including pharma, both a huge opportunity and a stimulating market access challenge, say Olaf Schoeman and […]
A new dawn for clinical trial management
It’s time for pharma to take a 360-degree view of its clinical trial data and step into the future with near real-time trial management. The […]
The key elements driving the success of digital health
Ahead of Frontiers Health 2020, steering committee members Roberto Ascione and Paul Tunnah from Healthware give us their thoughts on the trends driving the bright […]
Deep Dive: Digital Health Innovation 2020
Most of the digital health experts we spoke to for this issue of Deep Dive made one thing clear – no one can really say […]
Responding to dynamic shifts in value communications
OPEN Health’s Beth Lesher and Annemarie Clegg examine what the convergence of medical communications and market access means for pharmaceutical companies. Value in healthcare is […]
The tools and techniques making virtual patient simulations more realistic than ever
Patient simulations have been a key tool for educating physicians in some form for hundreds of years – and now cutting-edge technologies are helping them […]
Cutting through the noise for HCPs
In a world producing more content than ever before, getting information to time-poor HCPs can be incredibly difficult – even if they want to find […]
GSK’s John Fleming on rethinking oncology from the ground up
What if we could look at cancer treatment from a completely fresh perspective? This is the philosophy GSK’s UK country medical head for oncology, John […]
Commercialising innovative new medicines
As pharmaceutical ingenuity hits new heights, ensuring that patients gain access to innovative medicines requires a unique combination of evidence generation and communication Working with […]
How to increase haematologists’ and oncologists’ confidence with new treatments
A new whitepaper from Medscape highlights the difficulties haematologists and oncologists face in keeping up with rapid developments in treatment. We speak to the company’s […]
Clinical decision support tools will help oncologists manage complexity
Making treatment decisions is a tough choice for oncologists: a therapy might save or significantly extend one patient’s life but not deliver the desired outcome […]
